Table 1.
Baseline characteristics by study arm
|
Prime with ChAd |
Prime with BNT |
|||||||
|---|---|---|---|---|---|---|---|---|
| ChAd (n=180) | m1273 (n=181) | NVX (n=179) | Overall (n=540) | BNT (n=175) | m1273 (n=177) | NVX (n=180) | Overall (n=532) | |
| Age | ||||||||
| Mean (SD) | 63·0 (5·51) | 63·3 (5·55) | 63·1 (5·76) | 63·2 (5·60) | 61·9 (5·37) | 62·0 (5·92) | 62·2 (5·56) | 62·0 (5·61) |
| Median (range) | 64·4 (50·1–74·2) | 64·1 (50·2–74·4) | 64·2 (50·1–74·6) | 64·2 (50·1–74·6) | 62·3 (50·4–77·1) | 62·4 (50·0–77·7) | 62·7 (50·2–78·1) | 62·4 (50·0–78·1) |
| Gender | ||||||||
| Female | 87 (48%) | 80 (44%) | 74 (41%) | 241 (45%) | 80 (46%) | 68 (38%) | 62 (34%) | 210 (40%) |
| Male | 93 (52%) | 101 (56%) | 105 (59%) | 299 (55%) | 95 (54%) | 109 (62%) | 118 (66%) | 322 (61%) |
| Ethnicity | ||||||||
| White | 169 (94%) | 159 (88%) | 162 (91%) | 490 (91%) | 166 (95%) | 166 (94%) | 172 (96%) | 504 (95%) |
| Black | 1 (1%) | 1 (1%) | 3 (2%) | 5 (1%) | 3 (2%) | 2 (1%) | 3 (2%) | 8 (2%) |
| Asian | 4 (2%) | 11 (6%) | 9 (5%) | 24 (4%) | 3 (2%) | 5 (3%) | 2 (1%) | 10 (2%) |
| Mixed | 3 (2%) | 7 (4%) | 3 (2%) | 13 (2%) | 1 (1%) | 1 (1%) | 2 (1%) | 4 (1%) |
| Other | 3 (2%) | 3 (2%) | 2 (1%) | 8 (2%) | 2 (1%) | 3 (2%) | 1 (1%) | 6 (1%) |
| Comorbidities* | ||||||||
| Cardiovascular | 49 (27%) | 55 (30%) | 40 (22%) | 144 (27%) | 63 (36%) | 46 (26%) | 57 (32%) | 166 (31%) |
| Respiratory | 15 (8%) | 18 (10%) | 19 (11%) | 52 (10%) | 30 (17%) | 34 (19%) | 31 (17%) | 95 (18%) |
| Diabetes | 9 (5%) | 10 (6%) | 14 (8%) | 33 (6%) | 22 (13%) | 21 (12%) | 24 (13%) | 67 (13%) |
| Prime-boost interval (weeks) | ||||||||
| Mean (SD) | 9·4 (0·96) | 9·5 (0·95) | 9·5 (1·01) | 9·5 (0·97) | 9·5 (0·98) | 9·5 (0·95) | 9·6 (0·96) | 9·5 (0·96) |
| Median (range) | 9·4 (8·0–12·0) | 9·4 (8·0–12·0) | 9·4 (4·7† −11·9) | 9·4 (4·7–12·0) | 9·6 (8·0–11·9) | 9·4 (8·0–12·0) | 9·6 (8·0–11·9) | 9·6 (8·0–12·0) |
Data are n (%), mean (SD), or median (range). BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. m1273=mRNA-1273 vaccine, Moderna. NVX=NVXCoV2373 vaccine, Novavax.
*
Comorbidities were self-reported by participants, with review by study team doctor for assessment of severity. General practitioner confirmation was sought where needed. Included severities were those classified as mild, moderate, or well controlled.
†
Single participant boosted in error at 33 days, protocol deviation.